Nonlethal Inhibition of Gut Microbial Trimethylamine N-oxide Production Improves Cardiac Function and Remodeling in a Murine Model of Heart Failure.
Chelsea L. Organ,Zhen Li,Thomas E. Sharp,David J. Polhemus,Nilaksh Gupta,Traci T. Goodchild,W. H. Wilson Tang,Stanley L. Hazen,David J. Lefer
DOI: https://doi.org/10.1161/JAHA.119.016223
IF: 6.106
2020-05-13
Journal of the American Heart Association
Abstract:Background Patients at increased risk for coronary artery disease and adverse prognosis during heart failure exhibit increased levels of circulating trimethylamine N‐oxide (TMAO), a metabolite formed in the metabolism of dietary phosphatidylcholine. We investigated the efficacy of dietary withdrawal of TMAO as well as use of a gut microbe‐targeted inhibitor of TMAO production, on cardiac function and structure during heart failure. Methods and Results Male C57BLK/6J mice were fed either control diet, a diet containing TMAO (0.12% wt/wt), a diet containing choline (1% wt/wt), or a diet containing choline (1% wt/wt) plus a microbial choline trimethylamine lyase inhibitor, iodomethylcholine (0.06% wt/wt), starting 3 weeks before transverse aortic constriction. At 6 weeks after transverse aortic constriction, a subset of animals in the TMAO group were switched to a control diet for the remainder of the study. Left ventricular structure and function were monitored at 3‐week intervals. Withdrawal of TMAO from the diet attenuated adverse ventricular remodeling and improved cardiac function compared with the TMAO group. Similarly, inhibiting gut microbial conversion of choline to TMAO with a choline trimethylamine lyase inhibitor, iodomethylcholine, improved remodeling and cardiac function compared with the choline‐fed group. Conclusions These experimental findings are clinically relevant, and they demonstrate that TMAO levels are modifiable following long‐term exposure periods with either dietary withdrawal of TMAO or gut microbial blockade of TMAO generation. Furthermore, these therapeutic strategies to reduce circulating TMAO levels mitigate the negative effects of dietary choline and TMAO in heart failure. Nonstandard Abbreviations and Acronyms CVD cardiovascular disease HF heart failure LV left ventricular PSR Picrosirius red TAC transverse aortic constriction TMA trimethylamine TMAO trimethylamine N‐oxide WGA wheat germ agglutinin Clinical Perspective What Is New? Following development of heart failure in a pressure overload heart failure mouse model, dietary modification from a high to low content of choline or trimethylamine N‐oxide leads to lower circulating trimethylamine N‐oxide levels and attenuation of adverse cardiac remodeling. Similar anti–adverse ventricular remodeling effects are observed with direct nonlethal inhibition of gut microbiota‐dependent trimethylamine N‐oxide generation, providing proof of concept that dietary nutrient‐mediated gut microbial metabolism is mechanistically linked to adverse cardiac remodeling. What Are the Clinical Implications? Despite significant morbidity and mortality, dietary and lifestyle modification in the management of heart failure have primarily focused on salt restriction and exercise. The present studies support a role of gut microbe‐generated metabolites as contributors to cardio‐renal disease progression. They also support further studies to target specific dietary nutrients or microbial enzymes to prevent disease progression in patients with heart failure. Introduction Heart failure (HF) remains a leading cause of death, afflicting >6.5 million people in the United States 1 . It is predicted that by 2030 the prevalence of HF will increase ≈50% and will have an economic burden that exceeds ≈$70 billion in the United States alone. 1 With a limited number of effective drugs to treat HF, there is a necessity to focus on nutrition and lifestyle alterations in patients with HF. Currently, there is a limited set of dietary guidelines that have concentrated on limiting sodium and fluid consumption for HF patients. 2< -Abstract Truncated-
cardiac & cardiovascular systems